

Supplementary Information

Direct allylation of aromatic and α,β -unsaturated carboxamides under ruthenium catalysis

Mirim Kim, Satyasheel Sharma, Neeraj Kumar Mishra, Sangil Han, Jihye Park, Minyoung Kim, Youngmi Shin, Jong Hwan Kwak, Sang Hoon Han and In Su Kim*

School of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea

* Corresponding author. Tel.: +82-31-290-7788; fax: +82-31-292-8800; e-mail: insukim@skku.edu

List of the Contents

General methods -----	S2
General procedure for the synthesis of amides -----	S3
General procedure for the allylation of amides (3a–3u,5b–5d and 7a–7b) -----	S3
Selected optimization of the reaction conditions -----	S4
Kinetic Isotope Effect (KIE) experiment -----	S5
Control experiment using rhodium catalyst -----	S6
Characterization data for amides (1a–1u and 6a) -----	S7–S14
Characterization data for the allylation of amides (3a–3u, 5b–5d and 7a–7b) -----	S15–S27
References -----	S28
^1H NMR and ^{13}C NMR copies of all products -----	S29–S76

General methods

Commercially available reagents were used without additional purification, unless otherwise stated. Sealed tubes ($13 \times 100 \text{ mm}^2$) were purchased from Fischer Scientific and dried in oven for overnight and cooled under a stream of nitrogen prior to use. Thin layer chromatography was carried out using plates coated with Kieselgel 60F₂₅₄ (Merck). For flash column chromatography, E. Merck Kieselgel 60 (230-400 mesh) was used. Nuclear magnetic resonance spectra (¹H and ¹³C NMR) were recorded on a Bruker Unity 500 MHz and 700 MHz spectrometer for CDCl₃ solutions and chemical shifts are reported as parts per million (ppm) relative to, respectively, residual CHCl₃ δ_H (7.24 ppm) and CDCl₃ δ_C (77.23 ppm) as internal standards. Resonance patterns are reported with the notations s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). In addition, the notation br is used to indicate a broad signal. Coupling constants (*J*) are reported in hertz (Hz). IR spectra were recorded on a Varian 2000 Infrared spectrophotometer and are reported as cm⁻¹. High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-600 spectrometer.


General procedure for the synthesis of amides

To a stirred suspension of carboxylic acid (1.0 equiv.) in dry CH₂Cl₂ (30 mL) was added thionyl chloride (1.5 equiv.) at 0 °C and stirred for 1 h at room temperature. To this reaction mixture Et₃N (3 equiv) was added followed by the addition of corresponding amine (1.2 equiv). The reaction mixture was then stirred at room temperature for overnight. The reaction mixture was washed with H₂O and extracted with EtOAc (50 mL). The organic layer was dried over Mg₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography.

General procedure for the allylation of amides (3a–3u** and **5b–5d**)**


To an oven-dried sealed tube charged with *N,N*-diethylbenzamide (**1a**) (53.1 mg, 0.3 mmol, 1.0 equiv.), [Ru(*p*-cymene)Cl₂]₂ (9.2 mg, 5 mol %), AgSbF₆ (20.6 mg, 20 mol %), Cu(OAc)₂ (108 mg, 2 equiv.) in THF (1 mL) was added allyl methyl carbonate (**2a**) (69.6 mg, 0.6 mmol, 2 equiv.). The reaction mixture was allowed to stir at 80 °C for 20 h, and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc) to afford **3a** (35.8 mg) in 55% yield.

Selected optimization of the reaction conditions




entry	catalyst (mol %)	oxidant (equiv)	additive (mol %)	solvent	yield (%) of (3a:4a)
1	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	t-AmOH	30 (3:1)
2	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	MeOH	traces
3	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	MeCN	traces
4	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	CH ₂ Cl ₂	20 (4:1)
5	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	diglyme	24 (4:1)
6	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	DCE	28 (5:1)
7	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	toluene	19 (2.4:1)
8	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (2)	AgSbF ₆ (20)	DMSO	traces
9	[Ru(<i>p</i>-cymene)Cl₂]₂ (5)	Cu(OAc)₂ (2)	AgSbF₆ (20)	THF	55 (4.5:1)
10	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (1)	AgSbF ₆ (20)	THF	47 (4.3:1)
11	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ (0.5)	AgSbF ₆ (20)	THF	41 (4.2:1)
12	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)		AgSbF ₆ (20)	THF	traces
13	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	pivalic acid (2)	AgSbF ₆ (20)	THF	26 (4:1)
14	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	CsOAc (2)	AgSbF ₆ (20)	THF	traces
15	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (5)	Cu(OAc) ₂ ·H ₂ O (2)	AgSbF ₆ (20)	THF	42 (3:1)
16	[Ru(<i>p</i> -cymene)Cl ₂] ₂ (2.5)	Cu(OAc) ₂ (2)	AgSbF ₆ (10)	THF	38 (3.8:1)

Kinetic Isotope Effect (KIE) experiment




To an oven-dried sealed tube charged with phenyl(pyrrolidin-1-yl)methanone (**1f**) (52.5 mg, 0.3 mmol, 1.0 equiv.), $[\text{Ru}(p\text{-cymene})\text{Cl}_2]_2$ (9.2 mg, 5 mol %), AgSbF_6 (20.6 mg, 20 mol %), $\text{Cu}(\text{OAc})_2$ (108 mg, 2 equiv.) in THF (1 mL) was added allyl methyl carbonate (**2a**) (69.6 mg, 0.6 mmol, 2 equiv.) and tetradecane (59.5 mg, 0.3 mmol) as an internal standard. In another reaction tube, **deuterio-1f** (54.0 mg, 0.3 mmol, 1.0 equiv) was used instead of **1f**. The two reactions were allowed to stir at 80 °C. An aliquot of each reaction mixture was taken at the time of 5 min, 10 min, 15 min, and 20 min. The corresponding yield of each product was determined by GC-MS (tetradecane as an internal standard). A kinetic isotope effect value ($k_{\text{H}}/k_{\text{D}}$) of 1.28 was observed.


	Relative yield (%) based on tetradecane			
	5 min	10 min	15 min	20 min
3f (H)	26.75	37.246	41.187	45.781
deuterio-3f (D)	5.463	9.884	15.441	19.475



Control experiment using rhodium catalyst




To an oven-dried sealed tube charged with phenyl(pyrrolidin-1-yl)methanone (**1f**) (52.5 mg, 0.3 mmol, 1.0 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (9.3 mg, 5 mol %), AgSbF_6 (20.6 mg, 20 mol %), Cu(OAc)_2 (108 mg, 2 equiv.) in THF (1 mL) was added allyl methyl carbonate (**2a**) (69.6 mg, 0.6 mmol, 2 equiv.). The reaction mixture was allowed to stir at 80 °C for 20 h, and cooled to room temperature. The reaction mixture was diluted with EtOAc (3 mL) and concentrated in vacuo. The residue was purified by flash column chromatography (*n*-hexanes/EtOAc) to afford a mixture of **3a** and **4f** in 30% yield with 1:1 ratio.




Characterization data for amides (**1a–1u** and **6a**)

N,N-Diethylbenzamide (**1a**)¹




¹H NMR (700 MHz, CDCl₃) δ 7.37–7.33 (m, 5H), 3.53 (br s, 2H), 3.22 (br s, 2H), 1.22 (br s, 3H), 1.08 (br s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 171.2, 137.3, 129.0, 128.3, 126.2, 43.2, 39.2, 14.2, 12.9.

N-Methylbenzamide (**1b**)²




¹H NMR (700 MHz, CDCl₃) δ 7.76–7.75 (m, 2H), 7.47–7.45 (m, 1H), 7.40–7.38 (m, 2H), 6.44 (br s, 1H), 2.98 (d, *J* = 4.9 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 168.3, 134.6, 131.3, 128.5, 126.8, 26.8.

N,N-Dimethylbenzamide (**1c**)¹




¹H NMR (700 MHz, CDCl₃) δ 7.39–7.35 (m, 5H), 3.09 (s, 3H), 2.95 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 171.6, 136.3, 129.4, 128.3, 127.0, 39.5, 35.3.

Morpholino(phenyl)methanone (**1d**)³




¹H NMR (700 MHz, CDCl₃) δ 7.42–7.37 (m, 5H), 3.76–3.43 (m, 8H); ¹³C NMR (175 MHz, CDCl₃) δ 170.4, 135.3, 129.8, 128.5, 127.1, 66.9, 48.2, 42.5.

Phenyl(piperidin-1-yl)methanone (**1e**)⁴




¹H NMR (700 MHz, CDCl₃) δ 7.38–7.35 (m, 5H), 3.69 (br s, 2H), 3.32 (br s, 2H), 1.66–1.49 (m, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 170.3, 136.5, 129.3, 128.4, 126.7, 48.7, 43.1, 26.5, 25.6, 24.6.

Phenyl(pyrrolidin-1-yl)methanone (**1f**)⁴




¹H NMR (700 MHz, CDCl₃) δ 7.41–7.40 (m, 2H), 7.29–7.27 (m, 3H), 3.53 (m, 2H), 3.31 (m, 2H), 1.85–1.83 (m, 2H), 1.76–1.74 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.6, 137.2, 129.6, 128.1, 127.0, 49.5, 46.1, 26.3, 24.3.

(4-Methoxyphenyl)(pyrrolidin-1-yl)methanone (**1g**)⁴




¹H NMR (700 MHz, CDCl₃) δ 7.44–7.43 (m, 2H), 6.82–6.80 (m, 2H), 3.74 (s, 3H), 3.54 (br s, 2H), 3.39 (br s, 2H), 1.85–1.78 (m, 4H); ¹³C NMR (175 MHz, CDCl₃) δ 169.3, 160.7, 129.3, 129.1, 113.3, 55.2, 49.7, 46.2, 26.4, 24.4.

Pyrrolidin-1-yl(*p*-tolyl)methanone (**1h**)⁵




¹H NMR (700 MHz, CDCl₃) δ 7.38 (d, *J* = 7.9 Hz, 2H), 7.13 (d, *J* = 7.3 Hz, 2H), 3.58 (t, *J* = 6.4 Hz, 2H), 3.38 (t, *J* = 6.2 Hz, 2H), 2.32 (s, 3H), 1.90–1.88 (m, 2H), 1.81–1.80 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.7, 139.8, 134.3, 128.7, 127.1, 49.6, 46.1, 26.4, 24.4, 21.3.

Pyrrolidin-1-yl(4-(trifluoromethyl)phenyl)methanone (**1i**)⁴




¹H NMR (700 MHz, CDCl₃) δ 7.61 (d, *J* = 8.1 Hz, 2H), 7.57 (d, *J* = 8.0 Hz, 2H), 3.60 (t, *J* = 7.0 Hz, 2H), 3.34 (t, *J* = 6.5 Hz, 2H), 1.94–1.90 (m, 2H), 1.86–1.82 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.2, 140.7, 131.4 (*q*, *J*_{C-F} = 32.6 Hz), 127.4, 125.3 (*q*, *J*_{C-F} = 4.3 Hz), 124.5 (*q*, *J*_{C-F} = 270.7 Hz), 49.4, 46.2, 26.3, 24.3.

(4-Nitrophenyl)(pyrrolidin-1-yl)methanone (**1j**)⁴




¹H NMR (700 MHz, CDCl₃) δ 8.25–8.23 (m, 2H), 7.67–7.65 (m, 2H), 3.64 (t, *J* = 7.0 Hz, 2H), 3.36 (t, *J* = 6.6 Hz, 2H), 1.99–1.95 (m, 2H), 1.92–1.88 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 167.3, 148.4, 143.1, 128.1, 123.6, 49.4, 46.3, 26.3, 24.3.

(4-Chlorophenyl)(pyrrolidin-1-yl)methanone (**1k**)⁵




¹H NMR (700 MHz, CDCl₃) δ 7.46–7.44 (m, 2H), 7.36–7.34 (m, 2H), 3.61 (t, *J* = 7.0 Hz, 2H), 3.39 (t, *J* = 6.6 Hz, 2H), 1.96–1.92 (m, 2H), 1.88–1.84 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.5, 135.8, 135.5, 128.6, 128.5, 49.6, 46.2, 26.4, 24.4.

Pyrrolidin-1-yl(3-(trifluoromethyl)phenyl)methanone (**1l**)




¹H NMR (700 MHz, CDCl₃) δ 7.78 (s, 1H), 7.69 (d, *J* = 7.7 Hz, 1H), 7.65 (d, *J* = 7.2 Hz, 1H), 7.52 (t, *J* = 7.7 Hz, 1H), 3.64 (t, *J* = 7.0 Hz, 2H), 3.39 (t, *J* = 6.6 Hz, 2H), 1.98–1.94 (m, 2H), 1.90–1.87 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 137.9, 130.6 (q, *J*_{C-F} = 32.1 Hz), 128.9, 126.4 (q, *J*_{C-F} = 3.0 Hz), 124.5 (q, *J*_{C-F} = 270.7 Hz), 124.1 (q, *J*_{C-F} = 4.1 Hz), 49.5, 46.3, 26.4, 24.4; IR (KBr) ν 2974, 2877, 2191, 2620, 1565, 1428, 1399, 1340, 1265, 1203, 1155, 1079, 889, 800, 730 cm⁻¹; HRMS (EI) calcd for C₁₂H₁₂F₃NO [M]⁺ 243.0871, found 243.0875.

(3-Nitrophenyl)(pyrrolidin-1-yl)methanone (1m)⁶




¹H NMR (700 MHz, CDCl₃) δ 8.30–8.27 (m, 1H), 8.19–8.15 (m, 1H), 7.80–7.77 (m, 1H), 7.55–7.51 (m, 1H), 3.62–3.57 (m, 2H), 3.41–3.37 (m, 2H), 1.93–1.82 (m, 4H); ¹³C NMR (175 MHz, CDCl₃) δ 166.8, 147.8, 138.6, 133.1, 129.6, 124.4, 122.2, 49.5, 46.4, 26.3, 24.3.

(3-Chlorophenyl)(pyrrolidin-1-yl)methanone (1n)




¹H NMR (700 MHz, CDCl₃) δ 7.46 (s, 1H), 7.35–7.33 (m, 2H), 7.29 (t, *J* = 7.6 Hz, 1H), 3.59 (t, *J* = 7.0 Hz, 2H), 3.36 (t, *J* = 6.7 Hz, 2H), 1.94–1.90 (m, 2H), 1.86–1.82 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 138.9, 134.2, 129.8, 129.6, 127.3, 125.1, 49.5, 46.2, 26.3, 24.4; IR (KBr) ν 2972, 2876, 2162, 1620, 1564, 1476, 1426, 1400, 1339, 1202, 1157, 1078, 916, 888, 800, 768, 741 cm⁻¹; HRMS (EI) calcd for C₁₁H₁₂ClNO [M]⁺ 209.0607, found 209.0608.

Naphthalen-2-yl(pyrrolidin-1-yl)methanone (1o)⁵




¹H NMR (700 MHz, CDCl₃) δ 7.95 (s, 1H), 7.79–7.76 (m, 3H), 7.55 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.46–7.42 (m, 2H), 3.63 (t, *J* = 6.5 Hz, 2H), 3.38 (br s, 2H), 1.88 (br s, 2H), 1.77 (br s, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.6, 134.5, 133.7, 132.5, 128.4, 128.0, 127.7, 127.0, 126.9, 126.5, 124.4, 49.6, 46.2, 26.4, 24.4.

(2-Fluorophenyl)(pyrrolidin-1-yl)methanone (1p)




¹H NMR (700 MHz, CDCl₃) δ 7.39–7.32 (m, 2H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.05 (t, *J* = 8.9 Hz, 1H), 3.61 (t, *J* = 7.0 Hz, 2H), 3.27 (t, *J* = 6.7 Hz, 2H), 1.95–1.91 (m, 2H), 1.87–1.83 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 165.1, 157.5 (d, *J*_{C-F} = 245.5 Hz), 131.1 (d, *J*_{C-F} = 8.6 Hz), 128.8 (d, *J*_{C-F} = 3.0 Hz), 125.7 (d, *J*_{C-F} = 17.8 Hz), 124.4 (d, *J*_{C-F} = 13.6 Hz), 115.8 (d, *J*_{C-F} = 22.0 Hz), 47.8, 45.8, 25.8, 24.5; IR (KBr) ν 2975, 2879, 2151, 2040, 1626, 1484, 1453, 1421, 1340, 1268, 1222, 1157, 1098, 1027, 908, 817, 754, 730 cm⁻¹; HRMS (EI) calcd for C₁₁H₁₂FO [M]⁺ 193.0903, found 193.0902.

(2-Methoxyphenyl)(pyrrolidin-1-yl)methanone (1q)⁷



¹H NMR (700 MHz, CDCl₃) δ 7.07–7.05 (m, 1H), 7.00 (dd, *J* = 7.4, 1.7 Hz, 1H), 6.70 (t, *J* = 7.4 Hz, 1H), 6.67 (d, *J* = 8.4 Hz, 1H), 3.55 (s, 3H), 3.36 (t, *J* = 6.9 Hz, 2H), 2.95 (t, *J* = 6.6 Hz, 2H), 1.68–1.64 (m, 2H), 1.60–1.56 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 167.4, 155.0, 130.1, 127.4, 127.2, 120.5, 110.9, 55.3, 47.4, 45.2, 25.6, 24.3.


(6-Bromopyridin-2-yl)(pyrrolidin-1-yl)methanone (1r)



¹H NMR (700 MHz, CDCl₃) δ 7.87–7.85 (m, 1H), 7.67 (t, *J* = 7.7 Hz, 1H), 7.55–7.54 (m,


1H), 3.80 (t, J = 6.6 Hz, 2H), 3.68 (t, J = 6.3 Hz, 2H), 1.97–1.93 (m, 4H); ^{13}C NMR (175 MHz, CDCl_3) δ 164.4, 154.9, 140.0, 139.1, 129.2, 123.0, 49.1, 47.1, 26.7, 23.9; IR (KBr) ν 2971, 2877, 2038, 1622, 1549, 1452, 1402, 1337, 1265, 1156, 1119, 1075, 986, 813, 754 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{10}\text{H}_{11}\text{BrN}_2\text{O} [\text{M}]^+$ 254.0055, found 254.0053.

(1*H*-Indol-1-yl)(pyrrolidin-1-yl)methanone (1s**)⁸**




^1H NMR (700 MHz, CDCl_3) δ 7.86 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 3.4 Hz, 1H), 7.28 (t, J = 7.2 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 6.56 (s, 1H), 3.53 (br s, 4H), 1.84 (br s, 4H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.2, 135.7, 129.2, 125.5, 123.4, 121.7, 120.8, 114.2, 105.4, 48.6, 25.4.

Cyclohexenyl(pyrrolidin-1-yl)methanone (1t**)⁹**




^1H NMR (700 MHz, CDCl_3) δ 5.92–5.90 (m, 1H), 3.47–3.43 (m, 4H), 2.23–2.20 (m, 2H), 2.10–2.07 (m, 2H), 1.88–1.83 (m, 4H), 1.68–1.64 (m, 2H), 1.63–1.58 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 171.2, 135.7, 128.5, 48.7, 45.5, 26.2, 25.3, 24.8, 24.4, 22.1, 21.7.

(E)-2-Methyl-1-(pyrrolidin-1-yl)but-2-en-1-one (1u**)**



¹H NMR (700 MHz, CDCl₃) δ 5.64–5.60 (m, 1H), 3.34–3.31 (m, 4H), 1.75–1.71 (m, 7H), 1.58–1.57 (m, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 171.9, 133.5, 126.2, 48.6, 45.4, 26.1, 24.3, 13.4, 13.1; IR (KBr) ν 2972, 2874, 2057, 1659, 1606, 1418, 1340, 1163, 1037, 913, 837, 730 cm⁻¹; HRMS (EI) calcd for C₉H₁₅NO [M]⁺ 153.1154, found 153.1152.


N-(4-(Pyrrolidine-1-carbonyl)phenyl)acetamide (6a)



¹H NMR (700 MHz, CDCl₃) δ 8.33 (s, 1H), 7.50 (d, *J* = 8.4 Hz, 2H), 7.42 (t, *J* = 8.4 Hz, 2H), 3.62 (t, *J* = 6.9 Hz, 2H), 3.45–3.40 (m, 2H), 2.15 (s, 3H), 1.96–1.93 (m, 2H), 1.87–1.84 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.4, 168.9, 139.8, 132.1, 128.1, 119.2, 49.7, 46.3, 26.4, 24.4, 22.4; IR (KBr) ν 3245, 2973, 2878, 1695, 1602, 1526, 1435, 1310, 1258, 1175, 852 cm⁻¹; HRMS (EI) calcd for C₁₃H₁₆N₂O₂ [M]⁺ 232.1212, found 232.1214.


Characterization data for the allylation of amides (3a–3u, 5b–5d and 7a–7b)

2-Allyl-*N,N*-diethylbenzamide (3a)¹⁰




¹H NMR (700 MHz, CDCl₃) δ 7.33–7.31 (m, 1H), 7.29–7.26 (m, 1H), 7.25–7.23 (m, 1H), 7.19–7.17 (m, 1H), 5.95 (ddt, *J* = 16.9, 10.0, 6.7 Hz, 1H), 5.12–5.07 (m, 2H), 3.41 (d, *J* = 6.3 Hz, 3H), 3.13–3.10 (m, 2H), 1.30–1.27 (m, 4H), 1.07–1.03 (m, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 170.6, 136.8, 136.5, 136.2, 135.4, 129.6, 128.6, 127.6, 125.9, 116.2, 42.9, 38.6, 37.1, 13.8, 12.8; IR (KBr) ν 2972, 2927, 2191, 2015, 1627, 1427, 1287, 1086, 914, 755 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₉NO [M]⁺ 217.1467, found 217.1468.

2-Allyl-*N*-methylbenzamide (3b)¹¹



¹H NMR (700 MHz, CDCl₃) δ 7.36–7.32 (m, 2H), 7.22–7.19 (m, 2H), 5.99 (ddt, *J* = 17.0, 10.1, 6.3 Hz, 1H), 5.93 (br s, 1H), 5.05 (dq, *J* = 10.0, 1.4 Hz, 1H), 4.99 (dq, *J* = 17.0, 1.7 Hz, 1H), 3.53–3.52 (m, 2H), 2.92 (d, *J* = 4.9 Hz, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 170.5, 137.6, 137.5, 136.5, 130.4, 129.9, 127.2, 126.3, 115.9, 37.5, 26.5; IR (KBr) ν 3282, 3070, 2922, 2236, 2196, 2015, 1633, 1533, 1441, 1406, 1309, 1157, 996, 911, 745 cm⁻¹; HRMS (EI) calcd for C₁₁H₁₃NO [M]⁺ 175.0997, found 175.0990.


2-Allyl-*N,N*-dimethylbenzamide (3c)



3c

¹H NMR (700 MHz, CDCl₃) δ 7.33–7.30 (m, 1H), 7.29–7.22 (m, 2H), 7.18 (t, *J* = 7.4 Hz, 1H), 5.92 (ddt, *J* = 16.9, 10.0, 6.7 Hz, 1H), 5.09–5.05 (m, 2H), 3.41 (br s, 2H), 3.12 (s, 1H), 2.82 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 171.3, 136.6, 136.5, 136.4, 129.8, 128.9, 126.3, 126.0, 116.1, 38.8, 37.3, 34.6; IR (KBr) ν 2925, 2348, 2154, 1982, 1628, 1503, 1441, 1390, 1264, 1187, 1065, 995, 915, 748 cm⁻¹; HRMS (EI) calcd for C₁₂H₁₅NO [M]⁺ 189.1154, found 189.1158.


(2-Allylphenyl)(morpholino)methanone (3d)



3d


¹H NMR (700 MHz, CDCl₃) δ 7.30–7.27 (m, 1H), 7.26–7.19 (m, 2H), 7.15–7.12 (m, 1H), 5.88 (ddt, *J* = 16.8, 10.0, 6.8 Hz, 1H), 5.05–5.04 (m, 2H), 3.84–3.73 (m, 4H), 3.53–3.14 (m, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 169.8, 136.8, 136.5, 135.4, 130.1, 129.2, 126.3, 126.1, 116.4, 66.9, 66.8, 47.5, 41.9, 37.2; IR (KBr) ν 2913, 2852, 2330, 2186, 1985, 1629, 1424, 1361, 1275, 1254, 1111, 1012, 915, 843, 747 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₇NO₂ [M]⁺ 231.1259, found 231.1264.

(2-Allylphenyl)(piperidin-1-yl)methanone (3e)




¹H NMR (700 MHz, CDCl₃) δ 7.28–7.25 (m, 1H), 7.22 (d, *J* = 7.7 Hz, 1H), 7.20–7.17 (m, 1H), 7.14–7.12 (m, 1H), 5.91 (ddt, *J* = 16.8, 10.0, 6.9 Hz, 1H), 5.06–5.03 (m, 2H), 3.84–3.82 (m, 1H), 3.59–3.57 (m, 1H), 3.44–3.40 (m, 1H), 3.36–3.33 (m, 1H), 3.19–3.15 (m, 1H), 3.11–3.07 (m, 1H), 1.66–1.59 (m, 6H); ¹³C NMR (175 MHz, CDCl₃) δ 169.6, 136.6, 136.5, 136.4, 129.7, 128.7, 126.2, 125.8, 116.2, 48.1, 42.3, 37.2, 26.3, 25.6, 24.5; IR (KBr) ν 2927, 2853, 2338, 2188, 1983, 1626, 1429, 1272, 1120, 997, 912, 852, 746 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₉NO [M]⁺ 229.1467, found 229.1470.

(2-Allylphenyl)(pyrrolidin-1-yl)methanone (3f)



¹H NMR (700 MHz, CDCl₃) δ 7.32–7.29 (m, 1H), 7.26–7.20 (m, 3H), 5.92 (ddt, *J* = 16.9, 10.0, 6.8 Hz, 1H), 5.08–5.02 (m, 2H), 3.63 (t, *J* = 7.0 Hz, 2H), 3.44 (d, *J* = 6.8 Hz, 2H), 3.14 (t, *J* = 6.7 Hz, 2H), 1.96–1.92 (m, 2H), 1.85–1.81 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.6, 137.6, 136.7, 136.2, 129.8, 128.9, 126.3, 125.9, 115.9, 48.7, 45.4, 37.4, 25.9, 24.5; IR (KBr) ν 2971, 2874, 2329, 2157, 1977, 1622, 1416, 1338, 1251, 1187, 1111, 994, 911, 730 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₇NO [M]⁺ 215.1310, found 215.1306.


(2-Allyl-4-methoxyphenyl)(pyrrolidin-1-yl)methanone (3g)



¹H NMR (700 MHz, CDCl₃) δ 7.14 (d, *J* = 8.4 Hz, 1H), 6.77 (d, *J* = 2.5 Hz, 1H), 6.74 (dd, *J* = 8.3, 2.5 Hz, 1H), 5.90 (ddt, *J* = 16.9, 10.0, 6.8 Hz, 1H), 5.08–5.01 (m, 2H), 3.79 (s, 3H), 3.60


(t, $J = 7.0$ Hz, 2H), 3.42 (d, $J = 6.8$ Hz, 2H), 3.15 (t, $J = 6.7$ Hz, 2H), 1.95–1.91 (m, 2H), 1.83–1.79 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.8, 159.8, 138.4, 136.6, 130.2, 127.4, 116.0, 115.3, 111.4, 55.2, 48.8, 45.4, 37.5, 26.0, 24.6; IR (KBr) ν 2967, 2874, 2157, 1982, 1603, 1500, 1414, 1283, 1242, 1161, 1033, 910 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_2$ [M] $^+$ 245.1416, found 245.1412.

(2-Allyl-4-methylphenyl)(pyrrolidin-1-yl)methanone (3h)



^1H NMR (700 MHz, CDCl_3) δ 7.07 (d, $J = 7.7$ Hz, 1H), 7.02 (br s, 1H), 7.00 (d, $J = 7.6$ Hz, 1H), 5.87 (ddt, $J = 16.9, 10.0, 6.8$ Hz, 1H), 5.05–4.97 (m, 2H), 3.58 (t, $J = 7.2$ Hz, 2H), 3.37 (d, $J = 6.7$ Hz, 2H), 3.11 (t, $J = 6.7$ Hz, 2H), 2.30 (s, 3H), 1.92–1.88 (m, 2H), 1.80–1.76 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 169.9, 138.7, 136.9, 136.2, 134.8, 130.5, 126.9, 125.9, 115.7, 48.7, 45.4, 37.4, 25.9, 24.5, 21.2; IR (KBr) ν 2969, 2873, 2186, 2155, 1982, 1624, 1503, 1414, 1338, 1228, 1165, 994, 910, 820, 729 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{19}\text{NO}$ [M] $^+$ 229.1467, found 229.1467.


(2-Allyl-4-(trifluoromethyl)phenyl)(pyrrolidin-1-yl)methanone (3i)



^1H NMR (700 MHz, CDCl_3) δ 7.53–7.45 (m, 2H), 7.31 (d, $J = 7.8$ Hz, 1H), 5.88 (ddt, $J = 16.9, 10.0, 6.8$ Hz, 1H), 5.12–5.06 (m, 2H), 3.64 (t, $J = 7.0$ Hz, 2H), 3.47 (d, $J = 6.7$ Hz, 2H), 3.08 (t, $J = 6.7$ Hz, 2H), 1.96–1.92 (m, 2H), 1.88–1.82 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 168.2, 141.0, 137.5, 135.5, 131.1 (q, $J_{\text{C}-\text{F}} = 32.2$ Hz), 126.7 (q, $J_{\text{C}-\text{F}} = 4.0$ Hz), 126.4, 124.6 (q, $J_{\text{C}-\text{F}} = 4.0$ Hz).


$\text{F} = 270.8$ Hz), 123.3 (q, $J_{\text{C}-\text{F}} = 4.2$ Hz), 117.0, 48.6, 45.5, 37.2, 25.9, 24.5; IR (KBr) ν 2976, 2878, 2187, 2155, 1984, 1628, 1505, 1427, 1328, 1281, 1161, 1118, 1070, 994, 913, 833, 739 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{16}\text{F}_3\text{NO} [\text{M}]^+$ 283.1184, found 283.1181.

(2-Allyl-4-nitrophenyl)(pyrrolidin-1-yl)methanone (3j)




^1H NMR (700 MHz, CDCl_3) δ 8.10 (d, $J = 2.0$ Hz, 1H), 8.06 (dd, $J = 8.2, 2.1$ Hz, 1H), 7.36 (d, $J = 8.3$ Hz, 1H), 5.86 (ddt, $J = 16.4, 10.2, 6.8$ Hz, 1H), 5.12–5.09 (m, 2H), 3.61 (t, $J = 7.1$ Hz, 2H), 3.48 (d, $J = 6.7$ Hz, 2H), 3.08 (t, $J = 6.7$ Hz, 2H), 1.97–1.92 (m, 2H), 1.87–1.82 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 167.3, 148.0, 143.5, 138.8, 134.9, 127.1, 124.8, 121.6, 117.6, 48.5, 45.6, 37.1, 25.9, 24.4; IR (KBr) ν 2961, 2873, 2344, 2186, 2152, 1982, 1871, 1635, 1522, 1442, 1346, 1201 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_3 [\text{M}]^+$ 260.1161, found 260.1165.

(2-Allyl-4-chlorophenyl)(pyrrolidin-1-yl)methanone (3k)




^1H NMR (700 MHz, CDCl_3) δ 7.22 (d, $J = 1.9$ Hz, 1H), 7.18 (dd, $J = 8.1, 2.1$ Hz, 1H), 7.11 (d, $J = 8.0$ Hz, 1H), 5.84 (ddt, $J = 17.0, 10.0, 6.7$ Hz, 1H), 5.07–5.02 (m, 2H), 3.58 (t, $J = 7.0$ Hz, 2H), 3.37 (d, $J = 6.8$ Hz, 2H), 3.09 (t, $J = 6.7$ Hz, 2H), 1.93–1.89 (m, 2H), 1.82–1.78 (m, 2H); ^{13}C NMR (175 MHz, CDCl_3) δ 168.6, 138.5, 135.9, 135.7, 134.6, 129.9, 127.3, 126.5, 116.7, 48.7, 45.5, 37.9, 25.9, 24.5; IR (KBr) ν 2970, 2875, 2344, 2156, 1982, 1624, 1591, 1419, 1338, 1226, 1151, 1106, 994, 911, 864, 822, 766 cm^{-1} ; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{16}\text{ClNO} [\text{M}]^+$ 249.0920, found 249.0921.

(2-Allyl-5-(trifluoromethyl)phenyl)(pyrrolidin-1-yl)methanone (3l)




¹H NMR (700 MHz, CDCl₃) δ 7.54 (d, *J* = 8.0 Hz, 1H), 7.45 (br s, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 5.86 (ddt, *J* = 16.8, 10.0, 6.8 Hz, 1H), 5.08–5.04 (m, 2H), 3.61 (t, *J* = 7.0 Hz, 2H), 3.46 (d, *J* = 6.7 Hz, 2H), 3.10 (t, *J* = 6.7 Hz, 2H), 1.95–1.91 (m, 2H), 1.85–1.81 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 140.6, 138.1, 135.5, 128.7 (q, *J*_{C-F} = 32.7 Hz), 125.7 (q, *J*_{C-F} = 3.7 Hz), 125.3 (q, *J*_{C-F} = 272.1 Hz), 124.6, 123.0 (q, *J*_{C-F} = 3.2 Hz), 116.9, 48.7, 45.5, 37.2, 25.9, 24.4; IR (KBr) ν 2975, 2879, 2185, 2155, 1986, 1630, 1442, 1399, 1324, 1273, 1167, 1118, 1074, 994, 908, 842, 735 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₆F₃NO [M]⁺ 283.1184, found 283.1185.

(2-Allyl-5-nitrophenyl)(pyrrolidin-1-yl)methanone (3m)




¹H NMR (700 MHz, CDCl₃) δ 8.14 (dd, *J* = 8.4, 2.3 Hz, 1H), 8.00 (d, *J* = 2.3 Hz, 1H), 7.43 (d, *J* = 8.4 Hz, 1H), 5.86 (ddt, *J* = 16.4, 10.6, 6.7 Hz, 1H), 5.10–5.08 (m, 2H), 3.63 (t, *J* = 7.1 Hz, 2H), 3.52 (d, *J* = 6.7 Hz, 2H), 3.14 (t, *J* = 6.7 Hz, 2H), 1.98–1.94 (m, 2H), 1.88–1.84 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 166.9, 146.2, 144.4, 138.6, 134.8, 131.0, 123.8, 121.4, 117.5, 48.8, 45.7, 37.3, 26.0, 24.4; IR (KBr) ν 2971, 2876, 2344, 2155, 1986, 1627, 1520, 1435, 1398, 1339, 1226, 1155, 1075, 995, 909, 844, 739 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₆N₂O₃ [M]⁺ 260.1161, found 260.1163.

(2-Allyl-5-chlorophenyl)(pyrrolidin-1-yl)methanone (3n)




¹H NMR (700 MHz, CDCl₃) δ 7.35 (dd, *J* = 7.9, 2.2 Hz, 1H), 7.28–7.26 (m, 2H), 5.94 (ddt, *J* = 16.9, 10.0, 6.6 Hz, 1H), 5.15–5.10 (m, 2H), 3.68 (t, *J* = 7.0 Hz, 2H), 3.47 (d, *J* = 6.7 Hz, 2H), 3.22 (t, *J* = 6.7 Hz, 2H), 2.02–2.00 (m, 2H), 1.92–1.90 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 168.0, 139.0, 136.1, 134.8, 132.1, 131.1, 129.0, 126.0, 116.4, 48.7, 45.5, 36.7, 25.9, 24.5; IR (KBr) ν 2971, 2875, 2186, 1985, 1624, 1427, 1385, 1338, 1253, 1188, 1090, 994, 914, 813 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₆ClNO [M]⁺ 249.0920, found 249.0923.

(3-Allylnaphthalen-2-yl)(pyrrolidin-1-yl)methanone (3o)



¹H NMR (700 MHz, CDCl₃) δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.69 (s, 2H), 7.48–7.42 (m, 2H), 5.97 (ddt, *J* = 17.0, 10.0, 6.8 Hz, 1H), 5.13–5.06 (m, 2H), 3.66 (t, *J* = 7.1 Hz, 2H), 3.60 (d, *J* = 6.7 Hz, 2H), 3.17 (t, *J* = 6.7 Hz, 2H), 1.97–1.93 (m, 2H), 1.83–1.79 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.5, 136.7, 136.1, 134.1, 133.5, 131.6, 128.4, 127.7, 127.4, 126.7, 126.0, 125.0, 116.2, 49.0, 45.5, 37.5, 26.0, 24.6; IR (KBr) ν 2970, 2873, 2330, 2985, 1982, 1617, 1413, 1338, 1190, 995, 911, 809, 749 cm⁻¹; HRMS (EI) calcd for C₁₈H₁₉NO [M]⁺ 265.1467, found 265.1466.

(2-Allyl-6-fluorophenyl)(pyrrolidin-1-yl)methanone (3p)




¹H NMR (700 MHz, CDCl₃) δ 7.30–7.24 (m, 1H), 7.05 (d, *J* = 6.8 Hz, 1H), 6.96–6.91 (m, 1H), 5.91–5.85 (m, 1H), 5.09–5.03 (m, 2H), 3.74–3.64 (m, 1H), 3.61–3.57 (m, 1H), 3.52–3.49 (m, 1H), 3.37–3.32 (m, 1H), 3.28–3.24 (m, 1H), 3.12–3.07 (m, 1H), 1.90–1.78 (m, 4H); ¹³C NMR (175 MHz, CDCl₃) δ 164.5, 158.3 (d, *J*_{C-F} = 243.8 Hz), 139.1 (d, *J*_{C-F} = 4.1 Hz), 136.0, 130.1 (d, *J*_{C-F} = 8.8 Hz), 125.6 (d, *J*_{C-F} = 19.3 Hz), 125.4 (d, *J*_{C-F} = 2.6 Hz), 116.3, 113.4 (d, *J*_{C-F} = 22.4 Hz), 47.4, 45.4, 37.2, 25.7, 24.5; IR (KBr) ν 2975, 2878, 2329, 2158, 1986, 1628, 1576, 1459, 1422, 1339, 1242, 1197, 1111, 985, 913, 730 cm⁻¹; HRMS (EI) calcd for C₁₄H₁₆FNO [M]⁺ 233.1216, found 233.1215.

(2-Allyl-6-methoxyphenyl)(pyrrolidin-1-yl)methanone (3q)




¹H NMR (700 MHz, CDCl₃) δ 7.28–7.24 (m, 1H), 6.86 (d, *J* = 7.7 Hz, 1H), 6.78 (d, *J* = 8.3 Hz, 1H), 5.90 (ddt, *J* = 16.7, 10.0, 6.8 Hz, 1H), 5.09–5.02 (m, 2H), 3.82 (s, 3H), 3.75–3.72 (m, 1H), 3.60–3.57 (m, 1H), 3.43–3.40 (m, 1H), 3.34–3.31 (m, 1H), 3.20–3.17 (m, 1H), 3.07–3.04 (m, 1H), 1.97–1.92 (m, 2H), 1.89–1.77 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 167.2, 155.2, 137.7, 136.6, 129.5, 127.1, 121.9, 115.8, 108.7, 55.7, 47.2, 45.1, 37.3, 25.7, 24.6; IR (KBr) ν 2926, 2874, 2187, 1984, 1624, 1582, 1466, 1421, 1337, 1301, 1259, 1065, 995, 909, 762 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₉NO₂ [M]⁺ 245.1416, found 245.1418.

(3-Allyl-6-bromopyridin-2-yl)(pyrrolidin-1-yl)methanone (3r)




¹H NMR (700 MHz, CDCl₃) δ 7.48 (d, *J* = 8.1 Hz, 1H), 7.44 (d, *J* = 8.1 Hz, 1H), 5.88 (ddt, *J* = 16.9, 10.1, 6.7 Hz, 1H), 5.12–5.07 (m, 2H), 3.66 (t, *J* = 7.0 Hz, 2H), 3.46 (d, *J* = 6.7 Hz, 2H), 3.30 (t, *J* = 6.7 Hz, 2H), 1.99–1.93 (m, 2H), 1.91–1.86 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 165.2, 155.0, 140.9, 140.6, 138.6, 135.2, 131.9, 128.3, 117.2, 48.0, 45.6, 35.3, 26.0, 24.2; IR (KBr) ν 2964, 2877, 2235, 2016, 1626, 1550, 1453, 1405, 1260, 1121, 1076, 985, 916, 816, 756 cm⁻¹; HRMS (EI) calcd for C₁₃H₁₅BrN₂O [M]⁺ 294.0368, found 294.0365.

(2-Allyl-1*H*-indol-1-yl)(pyrrolidin-1-yl)methanone (3s)




¹H NMR (700 MHz, CDCl₃) δ 7.53 (d, *J* = 7.0 Hz, 1H), 7.21–7.17 (m, 2H), 7.13–7.10 (m, 1H), 6.36 (s, 1H), 5.94 (ddt, *J* = 17.0, 10.1, 6.7 Hz, 1H), 5.19–5.08 (m, 2H), 3.66–3.06 (m, 6H), 1.93 (br s, 4H); ¹³C NMR (175 MHz, CDCl₃) δ 152.5, 137.9, 135.1, 135.0, 128.4, 122.2, 120.8, 120.4, 116.8, 48.2, 47.1, 31.7, 25.6, 25.0; IR (KBr) ν 2970, 2881, 2237, 2193, 2018, 1676, 1452, 1399, 1339, 1295, 1188, 994, 915, 791 cm⁻¹; HRMS (EI) calcd for C₁₆H₁₈N₂O [M]⁺ 254.1419, found 254.1421.

(2-Allylcyclohex-1-enyl)(pyrrolidin-1-yl)methanone (3t)




¹H NMR (700 MHz, CDCl₃) δ 5.67 (ddt, *J* = 17.0, 10.1, 6.9 Hz, 1H), 4.96–5.90 (m, 2H), 3.42 (t, *J* = 6.8 Hz, 2H), 3.26 (t, *J* = 6.4 Hz, 2H), 2.66 (d, *J* = 6.9 Hz, 2H), 2.09 (br s, 2H), 1.92 (br s, 2H), 1.87–1.75 (m, 8H); ¹³C NMR (175 MHz, CDCl₃) δ 171.5, 135.5, 133.1, 132.1, 129.6, 116.1, 47.2, 45.9, 39.3, 29.6, 27.7, 25.9, 24.4, 22.4; IR (KBr) ν 2924, 2868, 2188, 2018, 1755, 1608, 1423, 1343, 1245, 1175, 1028, 963, 912, 741 cm⁻¹; HRMS (EI) calcd for C₁₄H₂₁NO [M]⁺ 219.1623, found 219.1623.

(Z)-2,3-Dimethyl-1-(pyrrolidin-1-yl)hexa-2,5-dien-1-one (3u)




¹H NMR (700 MHz, CDCl₃) δ 5.67 (ddt, *J* = 16.9, 10.1, 6.8 Hz, 1H), 5.09–4.97 (m, 2H), 3.47 (t, *J* = 7.0 Hz, 2H), 3.28 (t, *J* = 6.3 Hz, 2H), 2.73 (d, *J* = 6.7 Hz, 2H), 1.88–1.82 (m, 4H), 1.79 (s, 3H), 1.64 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 171.9, 135.5, 133.3, 130.7, 125.9, 116.1, 47.1, 44.9, 40.3, 25.8, 24.5, 16.5, 15.4; IR (KBr) ν 2972, 2876, 2059, 1725, 1608, 1423, 1339, 1249, 1190, 996, 911, 730 cm⁻¹; HRMS (EI) calcd for C₁₂H₁₉NO [M]⁺ 193.1467, found 193.1467.

(E)-(2-(But-2-enyl)phenyl)(pyrrolidin-1-yl)methanone (5b)




¹H NMR (700 MHz, CDCl₃) δ 7.29–7.27 (m, 3H), 7.21–7.16 (m, 1H), 5.57–5.46 (m, 2H), 3.63 (t, *J* = 7.0 Hz, 2H), 3.42 (d, *J* = 6.7 Hz, 2H), 3.13 (t, *J* = 6.7 Hz, 2H), 1.95–1.92 (m, 2H), 1.84–1.80 (m, 2H), 1.69–1.68 (m, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.8, 137.6, 137.3, 129.6, 128.9, 128.3, 126.1, 125.8, 125.0, 48.6, 45.3, 30.5, 26.0, 24.6, 12.9; IR (KBr) ν 2969, 2875, 2190, 2108, 1722, 1624, 1486, 1416, 1338, 1251, 1185, 1032, 969, 909, 750 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₉NO [M]⁺ 229.1467, found 229.1463.

(2-(2-Methylallyl)phenyl)(pyrrolidin-1-yl)methanone (5c)




¹H NMR (700 MHz, CDCl₃) δ 7.30–7.28 (m, 1H), 7.25–7.19 (m, 3H), 4.77 (s, 1H), 4.68 (s, 1H), 3.61 (t, *J* = 7.0 Hz, 2H), 3.41 (br s, 2H), 3.11 (t, *J* = 6.7 Hz, 2H), 1.94–1.90 (m, 2H), 1.82–1.78 (m, 2H), 1.66 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.7, 144.3, 137.9, 136.0, 130.4, 128.7, 126.2, 126.0, 112.1, 48.7, 45.3, 41.3, 26.0, 24.5, 22.2; IR (KBr) ν 2964, 2876, 2237, 2189, 2016, 1617, 1574, 1415, 1340, 1230, 1027, 923, 789, 714 cm⁻¹; HRMS (EI) calcd for C₁₅H₁₉NO [M]⁺ 229.1467, found 229.1467.

(2-(3-Methylbut-2-enyl)phenyl)(pyrrolidin-1-yl)methanone (5d)¹²




¹H NMR (700 MHz, CDCl₃) δ 7.28–7.26 (m, 1H), 7.23–7.22 (m, 1H), 7.20–7.16 (m, 2H), 5.23–5.21 (m, 1H), 3.62 (t, *J* = 7.1 Hz, 2H), 3.36 (d, *J* = 6.8 Hz, 2H), 3.12 (t, *J* = 6.7 Hz, 2H), 1.95–1.91 (m, 2H), 1.84–1.81 (m, 2H), 1.70 (s, 3H), 1.68 (s, 3H); ¹³C NMR (175 MHz, CDCl₃) δ 169.9, 137.9, 137.5, 132.7, 129.6, 128.8, 125.9, 125.8, 122.5, 48.6, 45.3, 31.7, 25.9, 25.8, 24.6, 17.9; IR (KBr) ν 2968, 2875, 2192, 2017, 1618, 1574, 1414, 1339, 1251, 1228, 1160, 1075, 1026, 918, 872, 790, 716, 699 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₁NO [M]⁺ 243.1623, found 243.1623.

(E)-1-(2-methyl-6-(prop-1-enyl)-5-(pyrrolidine-1-carbonyl)-1H-indol-1-yl)ethanone (7a)



¹H NMR (700 MHz, CDCl₃) δ 8.15 (s, 1H), 7.22 (s, 1H), 6.48–6.45 (m, 1H), 6.28 (s, 1H), 6.24–6.19 (m, 1H), 3.64 (t, *J* = 7.0 Hz, 2H), 3.05 (t, *J* = 6.8 Hz, 2H), 2.68 (s, 3H), 2.58 (s, 3H), 1.92–1.87 (m, 2H), 1.83 (d, *J* = 6.7 Hz, 3H), 1.80–1.76 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 170.2, 170.0, 138.1, 137.3, 132.2, 130.4, 128.5, 127.4, 117.2, 116.3, 112.5, 109.7, 48.3, 45.5, 27.4, 25.9, 24.7, 18.7, 17.7; IR (KBr) ν 2923, 2851, 1671, 1594, 1417, 1369, 1264, 1163, 732 cm⁻¹; HRMS (EI) calcd for C₁₉H₂₂N₂O₂ [M]⁺ 310.1681, found 310.1686.



***N*-(3-Allyl-4-(pyrrolidine-1-carbonyl)phenyl)acetamide (7b)**



¹H NMR (700 MHz, CDCl₃) δ 8.32 (s, 1H), 7.32 (d, *J* = 8.1 Hz, 1H), 7.21 (s, 1H), 7.03 (d, *J* = 8.1 Hz, 1H), 5.80 (ddt, *J* = 16.9, 10.0, 6.7 Hz, 1H), 5.03–4.97 (m, 2H), 3.59 (t, *J* = 7.1 Hz, 2H), 3.32 (d, *J* = 6.7 Hz, 2H), 3.11 (t, *J* = 6.7 Hz, 2H), 2.11 (s, 3H), 1.94–1.90 (m, 2H), 1.83–1.79 (m, 2H); ¹³C NMR (175 MHz, CDCl₃) δ 169.7, 168.9, 138.8, 137.1, 136.3, 132.9, 126.5, 121.3, 118.1, 116.1, 48.8, 45.5, 37.4, 25.9, 24.5, 24.3; IR (KBr) ν 2922, 2852, 1672, 1592, 1532, 1438, 1255, 1163, 732 cm⁻¹; HRMS (EI) calcd for C₁₆H₂₀N₂O₂ [M]⁺ 272.1525, found 272.1526.


References

1. C. Hu, X. Yan, X. Zhou and Z. Li, *Org. Biomol. Chem.*, 2013, **11**, 8179.
- ². Q. Xia, X. Liu, Y. Zhang, C. Chen and W. Chen, *Org. Lett.*, 2013, **15**, 3326.
3. P. Baburajan and K. P. Elango, *Tetrahedron Lett.*, 2014, **55**, 1006.
4. J. Bai, B. K. Zambróń and P. Vogel, *Org. Lett.*, 2014, **16**, 604.
5. R. Tank, U. Pathak, M. Vimal, S. Bhattacharyya and L. K. Pandey, *Green Chem.*, 2014, **13**, 3350.
6. G.-L. Li, K. K.-Y. Kung and M.-K. Wong, *Chem. Commun.*, 2012, **48**, 4112.
7. A. R. Katritzky, H.-Y. He and K. Suzuki, *J. Org. Chem.*, 2000, **65**, 8210.
8. C. G. Hartung, A. Fecher, B. Chapell and V. Snieckus, *Org. Lett.*, 2003, **5**, 1899.
9. C. M. Lindsay and D. A. Widdowson, *J. Chem. Soc. Perkin Trans. I*, 1998, 569.
10. H. Wang, N. Schröder and F. Glorius, *Angew. Chem., Int. Ed.*, 2013, **52**, 5386.
11. D. E. Korte, L. S. Hegedus and R. K. Wirth, *J. Org. Chem.*, 1977, **42**, 1329.
12. Y. J. Zhang, E. Skucas and M. J. Krische, *Org. Lett.*, 2009, **11**, 4248.




S30


SpinWorks 3: MR330-S




SpinWorks 3: MR330-S





SpinWorks 3: MR311-S




SpinWorks 3: MR311-S








SpinWorks 3: MR304P




SpinWorks 3: MR304P







SpinWorks 3: SH53




SpinWorks 3: SH53




SpinWorks 3: JB17




SpinWorks 3: JB17




SpinWorks 3: SH54




SpinWorks 3: SH54




SpinWorks 3: SH65




SpinWorks 3: SH65




SpinWorks 3: JB16




SpinWorks 3: JB16




SpinWorks 3: SH64




SpinWorks 3: SH64




SpinWorks 3: SH62




SpinWorks 3: SH62




SpinWorks 3: SH52




SpinWorks 3: SH52







SpinWorks 3: SH61




SpinWorks 3: SH61









SpinWorks 3: SH81P




SpinWorks 3: SH81P




SpinWorks 3: SH66




SpinWorks 3: SH66




SpinWorks 3: YM106




SpinWorks 3: YM106





SpinWorks 3: MY456




SpinWorks 3: MY456







SpinWorks 3: MR287P




SpinWorks 3: MR287P




SpinWorks 3: MR330P




SpinWorks 3: MR330P




SpinWorks 3: MR311P




SpinWorks 3: MR311P





SpinWorks 3: MR312P




SpinWorks 3: MR312P







SpinWorks 3: MR301P




SpinWorks 3: MR301P





SpinWorks 3: MR309P




SpinWorks 3: MR309P







SpinWorks 3: MR308P




SpinWorks 3: MR308P




SpinWorks 3: MR318P




SpinWorks 3: MR318P




SpinWorks 3: MR327P




SpinWorks 3: MR327P




SpinWorks 3: MR329P




SpinWorks 3: MR329P




SpinWorks 3: MR317P




SpinWorks 3: MR317P







SpinWorks 3: MR306P




SpinWorks 3: MR306P












SpinWorks 3: MR319P




SpinWorks 3: MR319P












SpinWorks 3: YM107P-2




SpinWorks 3: YM107P-2










SpinWorks 3: MR324P




SpinWorks 3: MR324P






SpinWorks 3: MR340P1



SpinWorks 3: MR340P1



SpinWorks 3: MR339P

